Fulcrum Therapeutics (NASDAQ:FULC) Director Robert Gould Sells 15,000 Shares

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Director Robert Gould sold 15,000 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $11.87, for a total transaction of $178,050.00. Following the completion of the sale, the director owned 469,864 shares of the company’s stock, valued at $5,577,285.68. The trade was a 3.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Fulcrum Therapeutics Trading Down 7.8%

Fulcrum Therapeutics stock traded down $0.85 on Tuesday, reaching $9.99. 818,459 shares of the stock were exchanged, compared to its average volume of 724,503. Fulcrum Therapeutics, Inc. has a twelve month low of $2.32 and a twelve month high of $15.74. The firm has a fifty day moving average price of $10.63 and a two-hundred day moving average price of $8.69. The stock has a market cap of $540.64 million, a PE ratio of -8.47 and a beta of 3.20.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.02). Equities analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of FULC. PharVision Advisers LLC bought a new stake in shares of Fulcrum Therapeutics in the 3rd quarter valued at about $220,000. Quarry LP acquired a new position in Fulcrum Therapeutics during the third quarter worth approximately $35,000. Nantahala Capital Management LLC raised its stake in Fulcrum Therapeutics by 8.9% in the third quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock valued at $42,971,000 after buying an additional 382,485 shares during the period. Millennium Management LLC raised its stake in Fulcrum Therapeutics by 42.7% in the third quarter. Millennium Management LLC now owns 150,867 shares of the company’s stock valued at $1,388,000 after buying an additional 45,174 shares during the period. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of Fulcrum Therapeutics in the third quarter valued at approximately $141,000. 89.83% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Stifel Nicolaus set a $25.00 price target on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Wednesday, October 8th. HC Wainwright increased their target price on shares of Fulcrum Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. The Goldman Sachs Group restated a “positive” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Finally, Truist Financial raised their price objective on shares of Fulcrum Therapeutics from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $19.00.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.